Poland and Taiwan moved to strengthen their biotechnology relationship at the Poland–Taiwan Biotechnology Forum, held on 17 July during BIO Asia–Taiwan 2026, as industry leaders and ecosystem representatives explored opportunities spanning clinical trials, biopharmaceutical manufacturing, technology collaboration and investment.

The forum brought together biotechnology leaders from both markets at a time when life sciences companies are increasingly looking beyond traditional innovation hubs to build more resilient and internationally connected development and manufacturing networks.

A central message emerged from the discussions: Poland and Taiwan possess highly complementary capabilities that could create a valuable bridge between the European and Asian biotechnology ecosystems.

Connecting Two Emerging Biotech Ecosystems

Opening the industry discussions, Marta Winiarska, President of the Board of BioInMed, presented an overview of Poland’s biotechnology sector and its growing position within Europe’s life sciences landscape.

Representing the Taiwanese perspective, Dr Wallace Lin, Secretary General of the Taiwan Bio Industry Organization, outlined Taiwan’s expanding biotechnology ecosystem and its strengths across pharmaceutical development, advanced manufacturing and healthcare innovation.

Together, the presentations established the strategic context for closer engagement between the two markets—combining Taiwan’s innovation and manufacturing capabilities with Poland’s access to European markets, scientific talent and growing life sciences infrastructure.

Poland Positions Itself as a Gateway to Europe

Mariusz Olejniczak, PhD, CEO of WPD Pharmaceuticals, examined Poland’s potential role as a gateway to Europe for pharmaceutical clinical trials and manufacturing.

As biotechnology companies increasingly pursue global development strategies from an earlier stage, access to efficient clinical research environments and scalable manufacturing capabilities has become a critical competitive consideration.

The discussion highlighted the opportunity for Taiwanese biotechnology companies seeking European expansion to consider Poland not simply as an individual market, but as a strategic base from which to access the broader European ecosystem.

Taking the conversation beyond conventional outsourcing models, Gregor Kawaletz, CEO of Mabion, explored how international biotechnology partnerships can evolve towards deeper, more integrated forms of collaboration.

His presentation, “Beyond Borders, Beyond Outsourcing,” reflected a broader shift taking place across the global biopharmaceutical industry: from transactional service relationships towards long-term partnerships built around shared capabilities, expertise and development objectives.

Mabion and KriSan Biotech Formalise Partnership

The forum’s most tangible milestone came with the signing of a partnership agreement between Mabion S.A. and Taiwan’s KriSan Biotech.

The ceremony followed a presentation by Jamie Hung, CEO and President of KriSan Biotech, who shared perspectives on successful Taiwan–Poland cooperation.

The agreement gave the forum a clear commercial dimension, demonstrating how bilateral industry engagement can progress from ecosystem discussions to concrete company-level partnerships.

For the wider biotechnology sector, the collaboration represents an example of how companies from Poland and Taiwan can combine capabilities and build cross-border relationships capable of supporting international growth.

Building a Wider Innovation and Investment Corridor

The session also introduced participants to Polish organisations represented at the Poland Pavilion at BIO Asia–Taiwan 2026, including OLIMP Laboratories and the Nencki Institute of Experimental Biology PAS, highlighting the diversity of Poland’s scientific and commercial biotechnology capabilities.

Further industry perspectives came from Benson Huang, Manager of Marketing & Sales at Formosa Laboratories, who shared another example of Taiwan–Poland cooperation and reinforced the growing potential for bilateral engagement across the pharmaceutical value chain.

Closing the business-focused discussions, Marcin Motyka, BDM at the Polish Investment and Trade Agency Taipei Office, presented investment opportunities in Poland, adding another dimension to the relationship beyond research and commercial partnerships.

From Cooperation to a Biotech Bridge Between Asia and Europe

The Poland–Taiwan Biotechnology Forum demonstrated that the opportunity between the two ecosystems extends well beyond market access.

For Taiwanese companies, Poland can provide a strategic connection to European clinical development, manufacturing, scientific capabilities and investment opportunities. For Polish biotechnology companies and research organisations, Taiwan offers access to one of Asia’s increasingly sophisticated life sciences ecosystems and a platform for wider regional engagement.

The Mabion–KriSan Biotech agreement provided the clearest evidence of this potential in action.

As biotechnology becomes increasingly global and partnership-driven, the next phase of Poland–Taiwan cooperation could be defined not simply by companies entering each other’s markets, but by jointly developing technologies, building manufacturing capabilities and creating pathways that connect innovation between Asia and Europe.

At BIO Asia–Taiwan 2026, that bridge moved one step closer to becoming a commercial reality.